Over the years, the selective targeting of IL-1β has been pursued but current recommendations limit the use of these compounds for people with acute gout or who have frequent flares, or who have contraindications or have not responded adequately to the standard treatment of colchicine, non-steroidal anti-inflammatory drugs and glucocorticoids [66,67] (Figure 1). Here, IL1B is linked to gout.